Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BMS 963272 is an inhibitor of monoacylglycerol acyltransferase 2 (MGAT-2; IC50 = 7.1 nM).1 It is selective for MGAT-2 over MGAT-3, acyl-CoA wax alcohol acyltransferase 2 (AWAT2), and diacylglycerol acyltransferase 2 (DGAT-2; IC50s = >33 µM for all). In vivo, BMS 963272 (30 mg/kg) reduces body weight gain and food intake in a wild-type but not Mogat2-/- mouse model of high-fat diet-induced obesity. BMS 963272 (0.3 and 3 mg/kg) reduces plasma alanine transaminase (ALT), aspartate aminotransferase (AST), and bile acid levels and hepatic fibrosis in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient and high-fat diet (CDAHFD).2
WARNING This product is not for human or veterinary use.
1. Screening hit to clinical candidate: Discovery of BMS-
2. MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity. Cell Metab. 34(11), 1732-1748 (2022).